Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00261-018-1592-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoplastic Pseudocirrhosis Pathophysiological Deepening.
Dig Dis Sci
December 2024
Department of Pathology, University of Modena and Reggio Emilia, Polyclinic Hospital, Via Del Pozzo, 41124, Modena, Italy.
The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer.
Cancers (Basel)
August 2024
Breast Unit, The Royal Marsden Hospital, London SW3 6JJ, UK.
Pseudocirrhosis is a diffuse nodularity of the liver that radiologically mimics cirrhosis but is a distinct pathological process. It is seen almost exclusively in patients with liver metastases and may represent a response to systemic treatment. Data on the risk factors for pseudocirrhosis and outcomes are limited.
View Article and Find Full Text PDF[Five Cases of Pseudocirrhosis during Eribulin Treatment for Breast Cancer].
Gan To Kagaku Ryoho
July 2024
Dept. of Medical Oncology, Osaka City General Hospital.
Article Synopsis
- Pseudocirrhosis can occur after chemotherapy for breast cancer with liver metastasis, resembling actual liver cirrhosis.
- A study reports on 5 patients treated with eribulin, a chemotherapy drug, who developed pseudocirrhosis during their treatment.
- Although liver metastases shrank significantly early on, these patients ultimately experienced poor health outcomes.
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.
BMC Pharmacol Toxicol
August 2024
Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.
Article Synopsis
- CDK4/6 inhibitors, like palbociclib, abemaciclib, and ribociclib, have revolutionized breast cancer treatment, but their varying side effects make it important to analyze their safety profiles.
- A study using real-world data from the FDA Adverse Event Reporting System (2015-2022) examined adverse events (AEs) associated with these drugs, employing multiple disproportionality methods to identify safety signals.
- Findings indicated that while all three inhibitors had common AEs, palbociclib showed higher risks for hematologic toxicities, ribociclib for macrocytosis and nail disorders, and abemaciclib for mucosal toxicity, highlighting the need for
An Atypical Presentation of Metastatic Breast Cancer as Acute Decompensated "Pseudocirrhosis".
Dig Dis Sci
September 2024
Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!